Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Jun. 30, 2021 | Sep. 02, 2021 | Dec. 31, 2020 | |
Document Information [Line Items] | |||
Entity Registrant Name | INTEGRATED BIOPHARMA INC | ||
Entity Central Index Key | 0001016504 | ||
Current Fiscal Year End Date | --06-30 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | true | ||
Entity Interactive Data Current | Yes | ||
Entity Common Stock, Shares Outstanding (in shares) | 29,820,277 | ||
Entity Public Float | $ 6,839,052 | ||
Entity Shell Company | false | ||
Document Type | 10-K | ||
Document Period End Date | Jun. 30, 2021 | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Title of 12(g) Security | Common Stock, $.002 par value per share |
Consolidated Statements of Inco
Consolidated Statements of Income (Unaudited) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Sales, net | $ 63,559 | $ 52,769 |
Cost of sales | 54,079 | 46,042 |
Gross profit | 9,480 | 6,727 |
Selling and administrative expenses | 3,696 | 3,468 |
Operating income | 5,784 | 3,259 |
Other income (expense), net: | ||
PPP Note forgiveness | 1,659 | |
Interest expense | (256) | (397) |
Unrealized (loss) gain on investment in iBio Stock | (53) | 103 |
Realized gains on sale of investment in iBio Stock | 56 | 72 |
Other income | 57 | 51 |
Total other income (expense), net | 1,463 | (171) |
Income before income taxes | 7,247 | 3,088 |
Income tax (benefit) expense, net | (766) | (1,020) |
Net income | $ 8,013 | $ 4,108 |
Basic net income per common share (in dollars per share) | $ 0.27 | $ 0.14 |
Diluted net income per common share (in dollars per share) | $ 0.25 | $ 0.13 |
Weighted average common shares outstanding - basic (in shares) | 29,699,065 | 29,572,255 |
Add: Equivalent shares outstanding - stock options (in shares) | 2,414,616 | 1,584,995 |
Weighted average common shares outstanding - diluted (in shares) | 32,113,681 | 31,157,250 |
Consolidated Balance Sheets (Cu
Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Jun. 30, 2021 | Jun. 30, 2020 |
Current Assets: | ||
Cash | $ 210 | $ 402 |
Accounts receivable, net | 5,776 | 5,507 |
Inventories | 11,695 | 10,101 |
Other current assets | 317 | 451 |
Total current assets | 17,998 | 16,461 |
Property and equipment, net | 1,742 | 1,696 |
Operating lease right-of-use assets (includes $2,322 and $2,788 with a related party) | 2,365 | 2,824 |
Deferred tax assets, net | 3,268 | 1,883 |
Security deposits and other assets | 67 | 80 |
Total Assets | 25,440 | 22,944 |
Current Liabilities: | ||
Advances under revolving credit facility | 2,173 | 4,046 |
Accounts payable (includes $65 and $62 due to a related party) | 3,496 | 4,358 |
Accrued expenses and other current liabilities | 1,610 | 1,384 |
Current portion of long term debt, net | 1,457 | 2,823 |
Current portion of operating lease liabilities (includes $485 and $467 due to a related party) | 500 | 488 |
Total current liabilities | 9,236 | 13,099 |
Long term debt, net | 1,436 | |
Operating lease liabilities (includes $1,842 and $2,327 due to a related party) | 1,870 | 2,342 |
Total Liabilities | 11,106 | 16,877 |
Commitments and Contingencies | ||
Stockholders' Equity | ||
Common Stock, $0.002 par value; 50,000,000 shares authorized; 29,782,543 and 29,680,843 shares issued and 29,747,643 and 29,645,943 shares outstanding, respectively | 60 | 59 |
Additional paid-in-capital | 50,516 | 50,263 |
Accumulated deficit | (36,143) | (44,156) |
Less: Treasury stock, at cost, 34,900 shares | (99) | (99) |
Total Stockholders' Equity | 14,334 | 6,067 |
Total Liabilities and Stockholders' Equity | $ 25,440 | $ 22,944 |
Consolidated Balance Sheets (_2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Jun. 30, 2021 | Jun. 30, 2020 |
Operating lease right-of-use assets | $ 2,365 | $ 2,824 |
Current portion of operating lease liabilities | 500 | 488 |
Operating lease liabilities | $ 1,870 | $ 2,342 |
Common stock, par value (in dollars per share) | $ 0.002 | $ 0.002 |
Common stock, shares authorized (in shares) | 50,000,000 | 50,000,000 |
Common stock, shares issued (in shares) | 29,838,177 | 29,680,843 |
Common stock, shares outstanding (in shares) | 29,803,277 | 29,645,943 |
Treasury stock, shares (in shares) | 34,900 | 34,900 |
Vitamin Realty LLC [Member] | ||
Operating lease right-of-use assets | $ 2,322 | $ 2,788 |
Accounts payable, related parties | 65 | 62 |
Current portion of operating lease liabilities | 485 | 467 |
Operating lease liabilities | $ 1,842 | $ 2,327 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Treasury Stock [Member] | Total |
Balance (in shares) at Jun. 30, 2019 | 29,600,843 | 34,900 | |||
Balance at Jun. 30, 2019 | $ 59 | $ 50,197 | $ (48,264) | $ (99) | $ 1,893 |
Compensation expense for employee stock options | 59 | $ 59 | |||
Shares issued upon exercise of stock options (in shares) | 80,000 | 80,000 | |||
Shares issued upon exercise of stock options | 7 | $ 7 | |||
Net income | 4,108 | 4,108 | |||
Balance (in shares) at Jun. 30, 2020 | 29,680,843 | 34,900 | |||
Balance at Jun. 30, 2020 | $ 59 | 50,263 | (44,156) | $ (99) | 6,067 |
Compensation expense for employee stock options | 231 | $ 231 | |||
Shares issued upon exercise of stock options (in shares) | 157,334 | 157,334 | |||
Shares issued upon exercise of stock options | $ 1 | 22 | $ 23 | ||
Net income | 8,013 | 8,013 | |||
Balance (in shares) at Jun. 30, 2021 | 29,838,177 | 34,900 | |||
Balance at Jun. 30, 2021 | $ 60 | $ 50,516 | $ (36,143) | $ (99) | $ 14,334 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 12 Months Ended | 14 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | |
Cash flows from operating activities: | |||
Net income | $ 8,013 | $ 4,108 | |
Adjustments to reconcile net income to net cash from operating activities: | |||
PPP Note forgiveness | 1,639 | ||
Amortization of operating lease right-of-use assets | 489 | 460 | |
Depreciation and amortization | 337 | 312 | |
Deferred income taxes | (1,385) | (1,349) | |
Accretion of financing instruments, amortization of prepaid financing costs and other | 42 | 22 | |
Compensation expense on employee stock options | 231 | 59 | |
Unrealized loss (gain) on investment in iBio Stock | 53 | (103) | |
Realized gain on sale of iBio Stock | (56) | (72) | |
Allowance for doubtful accounts | 25 | 15 | |
Gain on disposal of fixed assets | (14) | (4) | |
Changes in operating assets and liabilities: | |||
Accounts receivable | (294) | (1,082) | |
Inventories | (1,594) | (1,282) | |
Prepaid expenses and other assets | 43 | (7) | |
Operating lease obligations | (490) | (462) | |
Accounts payable | (937) | 487 | |
Accrued expenses and other current liabilities | 226 | 237 | |
Net cash provided by operating activities | 3,050 | 1,339 | |
Cash flows from investing activities: | |||
Purchase of property and equipment | (295) | (214) | |
Proceeds from sale of iBio Stock | 96 | 101 | |
Proceeds from sale of fixed assets | 3 | ||
Net cash used in investing activities | (199) | (110) | |
Cash flows from financing activities: | |||
Advances under revolving credit facility | 57,662 | 47,213 | |
Repayments of advances under revolving credit facility | (59,535) | (49,001) | |
Proceeds from issuance of note payable | 1,639 | ||
Proceeds from exercises of stock options | 23 | 7 | |
Repayments under term notes payable | (1,118) | (966) | |
Repayments under financed lease obligations | (75) | (194) | |
Net cash used in financing activities | (3,043) | (1,302) | |
Net decrease in cash | (192) | (73) | |
Cash at beginning of fiscal year | 402 | 475 | |
Cash at end of fiscal year | 210 | 402 | $ 210 |
Supplemental disclosures of cash flow information: | |||
Interest | 201 | 367 | |
Income taxes | 558 | 384 | |
Supplemental disclosures of non-cash transactions: | |||
Amount owed on purchase of fixed assets | 91 | 16 | |
Acquisition of right-of-use asset | 30 | ||
Trade in value on like-kind exchanges | 23 | ||
Paycheck Protection Program CARES Act [Member] | |||
Supplemental disclosures of non-cash transactions: | |||
Interest forgiven on PPP Note | $ 20 | $ 20 |
Note 1 - Business
Note 1 - Business | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1. Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company's customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company's business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Nutraceutical Businesses which includes the operations of AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Peaceful Sleep, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded products), (ii) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (iii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iv) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfillment services and (v) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 2. Principles of Consolidation. Reclassifications. Use of Estimates. not ● sales returns and allowances; ● allowance for doubtful accounts; ● inventory valuation; ● valuation and recoverability of long-lived assets; ● income taxes and valuation allowance on deferred income taxes, and; ● accruals for, and the probability of, the outcome of current litigation, if any. On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Revenue Recognition. 606, five ● identification of the promised goods or services in the contract; ● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract; ● measurement of the transaction price, including the constraint on variable consideration; ● allocation of the transaction price to the performance obligations based on estimated selling prices; and ● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Shipping and Handling Costs. $349 $287 June 30, 2021 2020, Stock-Based Compensation. two three Income Taxes not not The Company files a U.S. federal income tax return as well as returns for various states. The Company's income taxes have not 2014 2017 2016 2019, $23 June 30, 2019 no no June 30, 2021 2020. Leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not may We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component. Earnings Per Share. Fair Value of Financial Instruments. not In assessing the fair value of financial instruments, the Company uses a variety of methods and assumptions, which are based on estimates of market conditions and risks existing at the time. For certain instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments. All debt is based on current rates at which the Company could borrow funds with similar remaining maturities and approximates fair value. Accounts Receivable and Allowance for Doubtful Accounts. no 9 June 30, 2021 2020 $53 $99, Inventories. first first Property and Equipment. Building 15 Leasehold Improvements Shorter of estimated useful life or term of lease Machinery and Equipment 7 Transportation Equipment 5 Impairment of Long-Lived Assets. may not No June 30, 2021 2020 Investment in iBio, Inc. 2016 01 July 1, 2018, 6% August 2008. $2,562. 2016 01 June 30, 2021 2020, $56 $72, $53 $103 June 30, 2021 2020, June 30, 2021 2020, $67 $134, June 30, 2021 2020, June 30, 2021 2020 Accounting Pronouncements Recently Adopted On August 28, 2018, 2018 13, 820 820. 1 2 3 3 2018 13 July 1, 2020, 2018 13. not Accounting Pronouncements Not In June 2016, 2016 13 July 1, 2023, not In May 2019, 2020 05 326 2016 13. 2016 13 2016 13, July 1, 2023, not In March 2020, No. 2020 04, 848 not In October 2020, 2020 10, may may December 15, 2021, December 15, 2022. not 2020 10 |
Note 3 - Inventories
Note 3 - Inventories | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | Note 3. Inventories are stated at the lower of cost or net realizable value using the first first June 30, 2021 2020 Raw materials $ 7,941 $ 6,610 Work-in-process 2,942 2,612 Finished goods 812 879 Total $ 11,695 $ 10,101 |
Note 4 - Property and Equipment
Note 4 - Property and Equipment, Net | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | Note 4. Property and equipment consists of the following: June 30, 2021 2020 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,364 1,287 Machinery and equipment 6,416 6,465 Transportation equipment 6 6 9,036 9,008 Less: Accumulated depreciation and amortization (7,294 ) (7,312 ) Total $ 1,742 $ 1,696 Depreciation and amortization expense was $337 $312 June 30, 2021 2020, $309 $40 June 30, 2021 2020, $14 $55 not $4 June 30, 2021 2020, |
Note 5 - Senior Credit Facility
Note 5 - Senior Credit Facility and Other Long Term Debt | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 5. As of June 30, 2021 2020, Principal Amount Interest Rate Maturity Date June 30, 2021 2020 Revolving advances under Senior Credit Facility with PNC Bank, National Association $ 2,173 $ 4,046 3.25 % 5/15/2024 Installment Note with PNC Bank 1,466 2,584 3.50 % 5/15/2024 Payroll Protection Program Loan with PNC Bank - 1,639 1.00 % 6/28/2021 Financed lease obligations - 75 4.01% 7.28 % 12/1/2020 Total outstanding debt 3,639 8,344 Less: Revolving Advances (2,173 ) (4,046 ) Prepaid financing costs (9 ) (39 ) Current portion of long term debt, net (1,457 ) (2,823 ) Long term debt, net $ - $ 1,436 SENIOR CREDIT FACILITY On May 15, 2019, June 27, 2012, February 19, 2016. The Amended Loan Agreement provides for a total of $11,585 $8,000 $3,585 3.25% June 30, 2021 2020 2.50%. 3.50% June 30, 2021 2020 3.00%. Upon and after the occurrence of any event of default under the Amended Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. May 15, 2024 ( The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in eighty-four 84 first eighty-three 83 $43, first June 2019, first The Revolving Advances are subject to the terms and conditions set forth in the Amended Loan Agreement and are made in aggregate amounts at any time equal to the lesser of ( x $8,000 85%, 75%, 85% one may The Amended Loan Agreement contains customary mandatory prepayment provisions, including, without limitation the requirement to use any sales proceeds from the sale of iBio Stock to repay the Term Loan and to prepay the outstanding amount of the Term Note in an amount equal to twenty-five 25% June 30, 2016, not one hundred twenty 120 June 30, 2021, 25% June 30, 2016 $96 $101 June 30, 2021 2020, 25% June 30, 2021, $43, January 2022. In connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC. OTHER LONG TERM DEBT Paycheck Protection Program Term Note. June 30, 2021, June 28, 2021, $1,659 April 29, 2020, $1,639, $20, 1% April 30, 2022. 116 136 August 20, 2020, 2020 June 5, 2020. 1106 No 40% no April 29, 2020, June 28, 2021 ( no Financed Lease Obligations. February 25 April 25, 2020, February 14, 2018 April 17, 2018, $38 $15, $2 $1, 9.26% 9.38%, On November 1, 2019, December 22, 2017 $143, $6 6.56%. On December 1, 2020, February 1, 2019 $233, $10 7.28%. On December 1, 2020, December 8, 2015 $129, $2 4.01%. |
Note 6 - Interest Expense
Note 6 - Interest Expense | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Interest Expense [Text Block] | Note 6. The components of interest expense for the fiscal years ended June 30, 2021 2020 For the Fiscal Year Ended June 30, 2021 2020 Interest on Senior Debt $ 170 $ 336 Amortization of prepaid financing costs 42 22 Interest on PPP Note 19 - Interest on capitalized lease obligations 2 13 Other interest expense 23 26 Interest Expense $ 256 $ 397 The weighted average interest rate paid was 2.81% 4.71% June 30, 2021 2020, June 30, 2021 2020, $14 $19, |
Note 7 - Income Taxes
Note 7 - Income Taxes | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | Note 7. The components of the provision for income taxes consists of the following: For the fiscal year ended June 30, 2021 2020 Current - Federal $ - $ (40 ) Current - State and local 619 369 Deferred - Federal and state 1,190 549 Change in valuation allowance (2,575 ) (1,898 ) Income tax (benefit), net $ (766 ) $ (1,020 ) In the fiscal years ended June 30, 2021 $766 $1,020, A reconciliation of the statutory tax rate to the effective tax rate is as follows: For the fiscal year ended June 30, 2021 2020 Statutory federal income tax rate 21.0 % 21.0 % Statutory state income tax rate 9.5 % 9.5 % Other state income tax rate 2.5 % 2.5 % Change in valuation allowance (34.8 )% (69.0 )% PPP Note forgiveness (7.4 )% - Other temporary differences (1.4 )% 2.9 % Non-deductible expenses 0.0 % 0.1 % Effective income tax rate (10.6 )% (33.0 )% Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial accounting purposes and the amounts used for income tax reporting. Significant components of the Company's net deferred tax assets are as follows: June 30, 2021 2020 Deferred Tax Assets Net operating loss $ 5,691 $ 7,047 Capital loss carryover 299 258 Valuation adjustment on investment in iBio, Inc. 186 254 Depreciation (158 ) (204 ) Inventory 128 142 Other 195 34 Valuation allowance (3,073 ) (5,648 ) Total deferred tax asset, net $ 3,268 $ 1,883 The Company has net operating losses (“NOL”) of approximately $24,839 2025. $4,077 2022 2035. $1,423 $1,152 2025 $271 2026. June 30, 2020, Realization of the NOL carryforwards and other deferred tax temporary differences is contingent on future taxable earnings. The Company's deferred tax asset was reviewed for expected utilization using a “more likely than not” not” not June 30, 2021 2020, not” $2,575 $1,898, The Company will continue to assess and evaluate strategies that will enable the deferred tax asset, or portion thereof, to be utilized, and will reduce the valuation allowance appropriately at such time when it is determined that the “more likely than not” There were no June 30, 2021. no June 30, 2021 2020. The latest three four June 30, 2020 2014, 2015, 2016 2017 2016, 2017, 2018 2019. June 30, 2021 March 15, 2022. |
Note 8 - Profit-sharing Plan
Note 8 - Profit-sharing Plan | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Retirement Benefits [Text Block] | Note 8. The Company maintains a profit-sharing plan, which qualifies under Section 401 June 30, 2021 2020, $73 $68, |
Note 9 - Significant Risks and
Note 9 - Significant Risks and Uncertainties | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | Note 9. (a) Concentrations of Credit Risk-Cash. $250. June 30, 2021, $4 (b) Concentrations of Credit Risk-Receivables. not (c) Major Customers. June 30, 2021 2020, 92% two two 69% 26% June 30, 2021 2020. two 93% 92% June 30, 2021 2020, not 9% 10% June 30, 2021 2020, 10% (d) Business Risks. not The raw materials used by the Company are primarily commodities and agricultural-based products. Raw materials used by the Company in the manufacture of its nutraceutical products are purchased from independent suppliers. Raw materials are available from numerous sources and the Company believes that it will continue to obtain adequate supplies. Approximately 71% September 1, 2020 August 31, 2022. The continued global outbreak of COVID- 19, may one may may Additionally, a disruption in the supply chain for personal protection equipment (“PPE”) and cleaning supplies used in our manufacturing facilities could have an adverse effect on our operations. In accordance with our standard operating procedures and the updated guidelines issued by the Centers for Disease Control and Prevention (the “CDC”) for personal safety, adopted by The U.S. Department of Labor Occupational Safety and Health Administration, we are required to provide the PPE for our employees to wear while working. The inability to obtain timely PPE and cleaning supplies may In addition to supply chain issues resulting from the COVID- 19 Furthermore, the significant outbreak of this contagious disease in the human population has resulted in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for the Company's products and impact the Company's operating results. The Company does not may |
Note 10 - Commitments and Conti
Note 10 - Commitments and Contingencies | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 10. (a) Leases. 1 7 The components of lease expense for the fiscal year ended June 30, 2021 2020 2021 2020 Related Party - Vitamin Realty Other Leases Totals Related Party - Vitamin Realty Other Leases Totals Operating Lease Costs $ 566 $ 98 $ 664 $ 566 $ 104 $ 670 Finance Operating Lease Costs: Amortization of right-of use assets $ - $ 24 $ 24 $ - $ 57 $ 57 Interest on operating lease liabilities - 2 2 - 13 13 Total Finance Lease Costs $ - $ 26 $ 26 $ - $ 70 $ 70 Operating Lease Liabilities Related Party Operating Lease Liabilities. 100% January 5, 2012, second 74,898 76,161 January 31, 2026. $533, May 19, 2014, January 5, 2012, 2,700 January 31, 2020 June 1, 2024. $27 Rent expense, lease amortization costs and imputed interest costs on these related party leases were $883 $862 June 30, 2021 2020, June 30, 2021 2020, $65 $62, June 30, 2021 2020, $2,327 $2,794, Other Operating Lease Liabilities. May, 2023, As of June 30, 2021, Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 2,322 $ 485 $ 1,842 $ 2,537 Machinery and equipment leases 5 5 - 5 Office equipment leases 38 10 28 44 $ 2,365 $ 500 $ 1,870 $ 2,586 As of June 30, 2020, Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 2,788 $ 467 $ 2,327 $ 3,103 Machinery and equipment leases 16 11 5 16 Office equipment leases 20 10 10 22 $ 2,824 $ 488 $ 2,342 $ 3,141 As of June 30, 2021 2020, 3.75% 4.4 5.4 Supplemental cash flows information related to leases for the fiscal year ended June 30, 2021 Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 565 $ 98 $ 663 Operating cash flows from finance lease obligations - 2 2 Financing cash flows from finance lease obligations - 75 75 Supplemental cash flows information related to leases for the fiscal year ended June 30, 2020 Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 565 $ 92 $ 657 Operating cash flows from finance lease obligations - 13 13 Financing cash flows from finance lease obligations - 194 194 In the fiscal year ended June 30, 2021, one $25 five $7. Maturities of operating lease liabilities as of June 30, 2021 Year ending June 30, Operating Lease Commitment Related Party Operating Lease Commitment Total 2022 $ 17 $ 565 $ 582 2023 9 565 574 2024 9 563 572 2025 9 533 542 2026 5 311 316 Total minimum lease payments 49 2,537 2,586 Imputed interest (6 ) (210 ) (216 ) Total $ 43 $ 2,327 $ 2,370 Total rent expense, including real estate taxes and maintenance charges, was approximately $1,057 $1,040 June 30, 2021 2020, (b) Legal Proceedings. The Company is subject, from time to time, to claims by third |
Note 11 - Related Party Transac
Note 11 - Related Party Transactions | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 11. See Note 10 |
Note 12 - Equity Transactions a
Note 12 - Equity Transactions and Stock-based Compensation | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 12. Stock Option Plans. 7,000,000 6,000,000 13,000,000 2001 1997 5,000,000 may not ten 10% five June 30, 2021, 7,480,669 In November, 2020, 770,000 $0.65 $0.72, one three five ten June 30, 2021 2020, $231 $59. $307 two no June 30, 2020. The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended June 30, 2021: Risk Free Interest Rate 0.01% 0.78 % Volatility 134.5% 185.5 % Term 4.5 to 10 years Dividend Rate 0.00 % Closing Price of Common Stock $ 0.65 The Company calculates expected volatility for a stock-based grant based on historic daily stock price observations of its common stock during the period immediately preceding the grant that is equal in length to the expected term of the grant. The expected term of the options is estimated based on the Company's historical exercise rate and forfeiture rates are estimated based on employment termination experience. The risk free interest rate is based on U.S. Treasury yields for securities in effect at the time of grants with terms approximating the term of the grants. The assumptions used in the Black-Scholes option valuation model are highly subjective, and can materially affect the resulting valuations. In each of the fiscal years ended June 30, 2021 2020, no not The intrinsic value of options outstanding and exercisable at June 30, 2021 2020 $2,825 $846, A summary of the Company's stock option activity, and related information for the years ended June 30, Weighted Average Exercise Options Price Outstanding as of July 1, 2019 3,761,500 $ 0.16 Granted - - Exercised (80,000 ) 0.09 Terminated (137,500 ) 0.14 Expired (200,000 ) 0.10 Outstanding as of June 30, 2020 3,344,000 0.16 Granted 770,000 0.66 Exercised (157,334 ) 0.15 Terminated (3,333 ) 0.21 Expired (36,667 ) 0.21 Outstanding as of June 30, 2021 3,916,666 $ 0.26 Exercisable at June 30, 2020 2,875,533 $ 0.16 Exercisable at June 30, 2021 3,114,099 $ 0.19 The following table summarizes the range of exercise prices and weighted-average exercise prices for stock options outstanding and exercisable as of June 30, 2021 Weighted Weighted Weighted Average Average Average Remaining Exercise Range of Exercise Price Outstanding Exercise Price Contractual Life (years) Exercisable Price $ 0.09 - $ 0.10 1,301,000 $ 0.09 3.9 1,301,000 $ 0.09 $ 0.21 - $ 0.21 1,295,666 0.21 7.9 1,104,766 0.21 $ 0.23 - $ 0.25 550,000 0.23 5.4 508,333 0.23 $ 0.65 - $ 0.65 620,000 0.65 9.4 150,000 0.65 $ 0.72 - $ 0.72 150,000 0.72 6.9 50,000 0.72 $ 0.09 - $ 0.72 3,916,666 $ 0.26 6.7 3,114,099 $ 0.19 |
Note 13 - Segment Information
Note 13 - Segment Information | 12 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | Note 13. The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company's operating segments. The Company has divided its operations into two June 30, 2021 2020 $9,172 $8,473, Financial information relating to the fiscal years ended June 30, 2021 2020 Sales, Net Segment U.S. International Gross Capital Total Customers Customers Total Profit Depreciation Expenditures Assets Contract Manufacturing 2021 $ 52,763 $ 9,072 $ 61,835 $ 9,020 $ 332 $ 292 $ 21,333 2020 42,944 8,382 51,326 6,427 310 221 19,581 Other Nutraceutical Businesses 2021 1,624 100 1,724 460 5 3 4,107 2020 1,352 91 1,443 300 2 9 3,363 Total Company 2021 54,387 9,172 63,559 9,480 337 295 25,440 2020 44,296 8,473 52,769 6,727 312 230 22,944 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation. |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassifications. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates. not ● sales returns and allowances; ● allowance for doubtful accounts; ● inventory valuation; ● valuation and recoverability of long-lived assets; ● income taxes and valuation allowance on deferred income taxes, and; ● accruals for, and the probability of, the outcome of current litigation, if any. On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition. 606, five ● identification of the promised goods or services in the contract; ● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract; ● measurement of the transaction price, including the constraint on variable consideration; ● allocation of the transaction price to the performance obligations based on estimated selling prices; and ● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606. |
Cost of Goods, Shipping and Handling Costs [Policy Text Block] | Shipping and Handling Costs. $349 $287 June 30, 2021 2020, |
Share-based Payment Arrangement [Policy Text Block] | Stock-Based Compensation. two three |
Income Tax, Policy [Policy Text Block] | Income Taxes not not The Company files a U.S. federal income tax return as well as returns for various states. The Company's income taxes have not 2014 2017 2016 2019, $23 June 30, 2019 no no June 30, 2021 2020. |
Lessee, Leases [Policy Text Block] | Leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not may We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component. |
Earnings Per Share, Policy [Policy Text Block] | Earnings Per Share. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments. not In assessing the fair value of financial instruments, the Company uses a variety of methods and assumptions, which are based on estimates of market conditions and risks existing at the time. For certain instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments. All debt is based on current rates at which the Company could borrow funds with similar remaining maturities and approximates fair value. |
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block] | Accounts Receivable and Allowance for Doubtful Accounts. no 9 June 30, 2021 2020 $53 $99, |
Inventory, Policy [Policy Text Block] | Inventories. first first |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment. Building 15 Leasehold Improvements Shorter of estimated useful life or term of lease Machinery and Equipment 7 Transportation Equipment 5 |
Goodwill and Intangible Assets, Policy [Policy Text Block] | Impairment of Long-Lived Assets. may not No June 30, 2021 2020 |
Investment, Policy [Policy Text Block] | Investment in iBio, Inc. 2016 01 July 1, 2018, 6% August 2008. $2,562. 2016 01 June 30, 2021 2020, $56 $72, $53 $103 June 30, 2021 2020, June 30, 2021 2020, $67 $134, June 30, 2021 2020, June 30, 2021 2020 |
New Accounting Pronouncements, Policy [Policy Text Block] | Accounting Pronouncements Recently Adopted On August 28, 2018, 2018 13, 820 820. 1 2 3 3 2018 13 July 1, 2020, 2018 13. not Accounting Pronouncements Not In June 2016, 2016 13 July 1, 2023, not In May 2019, 2020 05 326 2016 13. 2016 13 2016 13, July 1, 2023, not In March 2020, No. 2020 04, 848 not In October 2020, 2020 10, may may December 15, 2021, December 15, 2022. not 2020 10 |
Note 3 - Inventories (Tables)
Note 3 - Inventories (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | June 30, 2021 2020 Raw materials $ 7,941 $ 6,610 Work-in-process 2,942 2,612 Finished goods 812 879 Total $ 11,695 $ 10,101 |
Note 4 - Property and Equipme_2
Note 4 - Property and Equipment, Net (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | June 30, 2021 2020 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,364 1,287 Machinery and equipment 6,416 6,465 Transportation equipment 6 6 9,036 9,008 Less: Accumulated depreciation and amortization (7,294 ) (7,312 ) Total $ 1,742 $ 1,696 |
Note 5 - Senior Credit Facili_2
Note 5 - Senior Credit Facility and Other Long Term Debt (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | Principal Amount Interest Rate Maturity Date June 30, 2021 2020 Revolving advances under Senior Credit Facility with PNC Bank, National Association $ 2,173 $ 4,046 3.25 % 5/15/2024 Installment Note with PNC Bank 1,466 2,584 3.50 % 5/15/2024 Payroll Protection Program Loan with PNC Bank - 1,639 1.00 % 6/28/2021 Financed lease obligations - 75 4.01% 7.28 % 12/1/2020 Total outstanding debt 3,639 8,344 Less: Revolving Advances (2,173 ) (4,046 ) Prepaid financing costs (9 ) (39 ) Current portion of long term debt, net (1,457 ) (2,823 ) Long term debt, net $ - $ 1,436 |
Note 6 - Interest Expense (Tabl
Note 6 - Interest Expense (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Interest Expense Disclosure Table [Table Text Block] | For the Fiscal Year Ended June 30, 2021 2020 Interest on Senior Debt $ 170 $ 336 Amortization of prepaid financing costs 42 22 Interest on PPP Note 19 - Interest on capitalized lease obligations 2 13 Other interest expense 23 26 Interest Expense $ 256 $ 397 |
Note 7 - Income Taxes (Tables)
Note 7 - Income Taxes (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | For the fiscal year ended June 30, 2021 2020 Current - Federal $ - $ (40 ) Current - State and local 619 369 Deferred - Federal and state 1,190 549 Change in valuation allowance (2,575 ) (1,898 ) Income tax (benefit), net $ (766 ) $ (1,020 ) |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | For the fiscal year ended June 30, 2021 2020 Statutory federal income tax rate 21.0 % 21.0 % Statutory state income tax rate 9.5 % 9.5 % Other state income tax rate 2.5 % 2.5 % Change in valuation allowance (34.8 )% (69.0 )% PPP Note forgiveness (7.4 )% - Other temporary differences (1.4 )% 2.9 % Non-deductible expenses 0.0 % 0.1 % Effective income tax rate (10.6 )% (33.0 )% |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | June 30, 2021 2020 Deferred Tax Assets Net operating loss $ 5,691 $ 7,047 Capital loss carryover 299 258 Valuation adjustment on investment in iBio, Inc. 186 254 Depreciation (158 ) (204 ) Inventory 128 142 Other 195 34 Valuation allowance (3,073 ) (5,648 ) Total deferred tax asset, net $ 3,268 $ 1,883 |
Note 10 - Commitments and Con_2
Note 10 - Commitments and Contingencies (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Lease, Cost [Table Text Block] | 2021 2020 Related Party - Vitamin Realty Other Leases Totals Related Party - Vitamin Realty Other Leases Totals Operating Lease Costs $ 566 $ 98 $ 664 $ 566 $ 104 $ 670 Finance Operating Lease Costs: Amortization of right-of use assets $ - $ 24 $ 24 $ - $ 57 $ 57 Interest on operating lease liabilities - 2 2 - 13 13 Total Finance Lease Costs $ - $ 26 $ 26 $ - $ 70 $ 70 |
Leases and Remaining Commitments [Table Text Block] | Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 2,322 $ 485 $ 1,842 $ 2,537 Machinery and equipment leases 5 5 - 5 Office equipment leases 38 10 28 44 $ 2,365 $ 500 $ 1,870 $ 2,586 Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 2,788 $ 467 $ 2,327 $ 3,103 Machinery and equipment leases 16 11 5 16 Office equipment leases 20 10 10 22 $ 2,824 $ 488 $ 2,342 $ 3,141 |
Supplemental Cash Flow Information, Leases [Table Text Block] | Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 565 $ 98 $ 663 Operating cash flows from finance lease obligations - 2 2 Financing cash flows from finance lease obligations - 75 75 Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 565 $ 92 $ 657 Operating cash flows from finance lease obligations - 13 13 Financing cash flows from finance lease obligations - 194 194 |
Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block] | Year ending June 30, Operating Lease Commitment Related Party Operating Lease Commitment Total 2022 $ 17 $ 565 $ 582 2023 9 565 574 2024 9 563 572 2025 9 533 542 2026 5 311 316 Total minimum lease payments 49 2,537 2,586 Imputed interest (6 ) (210 ) (216 ) Total $ 43 $ 2,327 $ 2,370 |
Note 12 - Equity Transactions_2
Note 12 - Equity Transactions and Stock-based Compensation (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Risk Free Interest Rate 0.01% 0.78 % Volatility 134.5% 185.5 % Term 4.5 to 10 years Dividend Rate 0.00 % Closing Price of Common Stock $ 0.65 |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Weighted Average Exercise Options Price Outstanding as of July 1, 2019 3,761,500 $ 0.16 Granted - - Exercised (80,000 ) 0.09 Terminated (137,500 ) 0.14 Expired (200,000 ) 0.10 Outstanding as of June 30, 2020 3,344,000 0.16 Granted 770,000 0.66 Exercised (157,334 ) 0.15 Terminated (3,333 ) 0.21 Expired (36,667 ) 0.21 Outstanding as of June 30, 2021 3,916,666 $ 0.26 Exercisable at June 30, 2020 2,875,533 $ 0.16 Exercisable at June 30, 2021 3,114,099 $ 0.19 |
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] | Weighted Weighted Weighted Average Average Average Remaining Exercise Range of Exercise Price Outstanding Exercise Price Contractual Life (years) Exercisable Price $ 0.09 - $ 0.10 1,301,000 $ 0.09 3.9 1,301,000 $ 0.09 $ 0.21 - $ 0.21 1,295,666 0.21 7.9 1,104,766 0.21 $ 0.23 - $ 0.25 550,000 0.23 5.4 508,333 0.23 $ 0.65 - $ 0.65 620,000 0.65 9.4 150,000 0.65 $ 0.72 - $ 0.72 150,000 0.72 6.9 50,000 0.72 $ 0.09 - $ 0.72 3,916,666 $ 0.26 6.7 3,114,099 $ 0.19 |
Note 13 - Segment Information (
Note 13 - Segment Information (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | Sales, Net Segment U.S. International Gross Capital Total Customers Customers Total Profit Depreciation Expenditures Assets Contract Manufacturing 2021 $ 52,763 $ 9,072 $ 61,835 $ 9,020 $ 332 $ 292 $ 21,333 2020 42,944 8,382 51,326 6,427 310 221 19,581 Other Nutraceutical Businesses 2021 1,624 100 1,724 460 5 3 4,107 2020 1,352 91 1,443 300 2 9 3,363 Total Company 2021 54,387 9,172 63,559 9,480 337 295 25,440 2020 44,296 8,473 52,769 6,727 312 230 22,944 |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Cost of Goods and Services Sold, Total | $ 54,079 | $ 46,042 |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | |
Income Tax (Expense) Benefit, Continuing Operations, Government Grants | $ 23 | |
Liability for Uncertainty in Income Taxes, Current | 0 | 0 |
Accounts Receivable, Allowance for Credit Loss, Ending Balance | 53 | 99 |
Impairment of Intangible Assets, Finite-lived | $ 0 | 0 |
Cost Method Investment, Ownership Percentage | 6.00% | |
Asset Impairment Charges, Total | $ 2,562 | |
Realized Investment Gains (Losses), Total | 56 | 72 |
Unrealized Gain (Loss) on Investments, Total | (53) | 103 |
Investment Owned, at Fair Value | $ 67 | $ 134 |
Building and Building Improvements [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 15 years | |
Machinery and Equipment [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 7 years | |
Air Transportation Equipment [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 5 years | |
State and Local Jurisdiction [Member] | New Jersey Division of Taxation [Member] | MDC [Member] | ||
Income Tax Examination, Year under Examination | 2014 2015 2016 2017 | |
State and Local Jurisdiction [Member] | New Jersey Division of Taxation [Member] | CII [Member] | ||
Income Tax Examination, Year under Examination | 2016 2017 2018 2019 | |
Shipping and Handling [Member] | ||
Cost of Goods and Services Sold, Total | $ 349 | $ 287 |
Note 3 - Inventories - Inventor
Note 3 - Inventories - Inventories (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Jun. 30, 2020 |
Raw materials | $ 7,941 | $ 6,610 |
Work-in-process | 2,942 | 2,612 |
Finished goods | 812 | 879 |
Total | $ 11,695 | $ 10,101 |
Note 4 - Property and Equipme_3
Note 4 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Depreciation, Total | $ 337 | $ 312 |
Gain (Loss) on Disposition of Property Plant Equipment, Total | 14 | 4 |
Fully Depreciated Property [Member] | ||
Property, Plant and Equipment, Disposals | 309 | 40 |
Gain (Loss) on Disposition of Property Plant Equipment, Total | 14 | 14 |
Property Not Fully Depreciated [Member] | ||
Property, Plant and Equipment, Disposals | 55 | 55 |
Equipment [Member] | ||
Gain (Loss) on Disposition of Property Plant Equipment, Total | $ 4 | $ 4 |
Note 4 - Property and Equipme_4
Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Jun. 30, 2020 |
Property and equipment, gross | $ 9,036 | $ 9,008 |
Less: Accumulated depreciation and amortization | (7,294) | (7,312) |
Total | 1,742 | 1,696 |
Land and Building [Member] | ||
Property and equipment, gross | 1,250 | 1,250 |
Leasehold Improvements [Member] | ||
Property and equipment, gross | 1,364 | 1,287 |
Machinery and Equipment [Member] | ||
Property and equipment, gross | 6,416 | 6,465 |
Transportation Equipment [Member] | ||
Property and equipment, gross | $ 6 | $ 6 |
Note 5 - Senior Credit Facili_3
Note 5 - Senior Credit Facility and Other Long Term Debt (Details Textual) - USD ($) $ in Thousands | Apr. 29, 2020 | May 15, 2019 | Feb. 01, 2019 | Apr. 17, 2018 | Feb. 14, 2018 | Dec. 22, 2017 | Dec. 08, 2015 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 |
Proceeds from Sale, Maturity and Collection of Investments, Total | $ 96 | $ 101 | ||||||||
Gains Losses on Extinguishment of Debt Including Interest | 1,659 | |||||||||
Proceeds from Notes Payable, Total | 1,639 | |||||||||
Finance Lease, Liability, Total | 75 | |||||||||
Marlin Equipment Finance [Member] | ||||||||||
Finance Lease, Liability, Total | $ 15 | $ 38 | ||||||||
First American Equipment Finance [Member] | ||||||||||
Finance Lease, Liability, Total | $ 233 | $ 143 | ||||||||
Wells Fargo Equipment Finance, Manufacturer Services Group [Member] | ||||||||||
Finance Lease, Liability, Total | $ 129 | |||||||||
iBio Stock [Member] | ||||||||||
Proceeds from Sale, Maturity and Collection of Investments, Total | $ 96 | $ 101 | ||||||||
Capital Lease [Member] | Marlin Equipment Finance [Member] | ||||||||||
Debt Instrument, Periodic Payment, Total | $ 1 | $ 2 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.38% | 9.26% | ||||||||
Capital Lease [Member] | First American Equipment Finance [Member] | ||||||||||
Debt Instrument, Periodic Payment, Total | $ 10 | $ 6 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 7.28% | 6.56% | ||||||||
Capital Lease [Member] | Wells Fargo Equipment Finance, Manufacturer Services Group [Member] | ||||||||||
Debt Instrument, Periodic Payment, Total | $ 2 | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.01% | |||||||||
Amended Loan Agreement [Member] | ||||||||||
Senior Notes, Total | $ 11,585 | |||||||||
Debt Instrument, Debt Default, Interest Rate Basic Spread | 2.00% | |||||||||
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow | 25.00% | 25.00% | ||||||||
Amended Loan Agreement [Member] | Term Loan [Member] | ||||||||||
Debt Instrument, Face Amount | $ 3,585 | |||||||||
Line of Credit Facility, Interest Rate at Period End | 3.50% | 3.50% | 3.50% | |||||||
Number of Consecutive Monthly Installments | 84 | |||||||||
Number of Consecutive Monthly Installments, Fixed Amount | 83 | |||||||||
Debt Instrument, Periodic Payment, Total | $ 43 | |||||||||
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow | 25.00% | |||||||||
Amended Loan Agreement [Member] | Term Loan [Member] | Eurodollar [Member] | ||||||||||
Debt Instrument, Basis Spread on Variable Rate | 3.00% | |||||||||
Amended Loan Agreement [Member] | Revolving Credit Facility [Member] | ||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 8,000 | |||||||||
Line of Credit Facility, Interest Rate at Period End | 3.25% | 3.25% | 3.25% | |||||||
Line of Credit Facility Covenant Maximum Aggregate Revolving Advance | $ 8,000 | |||||||||
Line of Credit Facility Covenant Aggregate Revolving Advance Receivables Advance Rate | 85.00% | |||||||||
Line of Credit Facility Covenant Aggregate Revolving Advance Inventory Advance Rate | 75.00% | |||||||||
Line of Credit Facility, Covenan,t Aggregate Revolving Advance, Appraised Liquidation Value, Inventory Advance Rate | 85.00% | |||||||||
Amended Loan Agreement [Member] | Revolving Credit Facility [Member] | Eurodollar [Member] | ||||||||||
Debt Instrument, Basis Spread on Variable Rate | 2.50% | 25.00% | ||||||||
Paycheck Protection Program CARES Act [Member] | ||||||||||
Gains Losses on Extinguishment of Debt Including Interest | $ 1,659 | |||||||||
Proceeds from Notes Payable, Total | $ 1,639 | |||||||||
Debt Instrument, Increase, Accrued Interest | $ 20 | $ 20 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 1.00% | 1.00% |
Note 5 - Senior Credit Facili_4
Note 5 - Senior Credit Facility and Other Long Term Debt - Debt Outstanding (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Financed lease obligations | $ 75 | |
Total outstanding debt | 3,639 | 8,344 |
Prepaid financing costs | (9) | (39) |
Current portion of long term debt, net | (1,457) | (2,823) |
Long term debt, net | 1,436 | |
Capital Lease [Member] | ||
Maturity Date | Dec. 1, 2020 | |
Convertible Debt [Member] | ||
Current portion of long term debt, net | $ (1,457) | (2,823) |
Minimum [Member] | Capital Lease [Member] | ||
Interest Rate | 4.01% | |
Maximum [Member] | Capital Lease [Member] | ||
Interest Rate | 7.28% | |
Paycheck Protection Program CARES Act [Member] | ||
Notes Payable | 1,639 | |
Interest Rate | 1.00% | |
Maturity Date | Jun. 28, 2021 | |
Revolving Advances [Member] | ||
Notes Payable | $ 2,173 | 4,046 |
Interest Rate | 3.25% | |
Maturity Date | May 15, 2024 | |
Less: Revolving Advances | $ (2,173) | (4,046) |
Installment Note with PNC Bank [Member] | ||
Notes Payable | $ 1,466 | $ 2,584 |
Interest Rate | 3.50% | |
Maturity Date | May 15, 2024 |
Note 6 - Interest Expense (Deta
Note 6 - Interest Expense (Details Textual) - USD ($) $ in Thousands | Jun. 30, 2021 | Jun. 30, 2020 |
Interest Payable | $ 14 | $ 19 |
Debt Related to Interest Expense [Member] | ||
Debt, Weighted Average Interest Rate | 2.81% | 4.71% |
Note 6 - Interest Expense - Int
Note 6 - Interest Expense - Interest Expense Components (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Interest on Senior Debt | $ 19 | |
Amortization of prepaid financing costs | 42 | 22 |
Interest on capitalized lease obligations | 2 | 13 |
Other interest expense | 23 | 26 |
Interest Expense | 256 | 397 |
Senior Notes [Member] | ||
Interest on Senior Debt | $ 170 | $ 336 |
Note 7 - Income Taxes (Details
Note 7 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Income Tax Expense (Benefit), Total | $ (766) | $ (1,020) |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | (2,575) | (1,898) |
Liability for Uncertainty in Income Taxes, Current | 0 | 0 |
Income Tax Examination, Penalties and Interest Accrued, Total | 0 | 0 |
Deferred Tax Assets Related to Net Operating Loss [Member] | ||
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | (2,575) | $ (1,898) |
Capital Loss Carryforward [Member] | ||
Tax Credit Carryforward, Amount | 1,423 | |
Capital Loss Carryforward [Member] | Tax Year 2025 [Member] | ||
Tax Credit Carryforward, Amount | 1,152 | |
Capital Loss Carryforward [Member] | Tax Year 2026 [Member] | ||
Tax Credit Carryforward, Amount | 271 | |
Domestic Tax Authority [Member] | ||
Operating Loss Carryforwards, Total | 24,839 | |
State and Local Jurisdiction [Member] | ||
Operating Loss Carryforwards, Total | $ 4,077 | |
State and Local Jurisdiction [Member] | New Jersey Division of Taxation [Member] | MDC [Member] | ||
Income Tax Examination, Year under Examination | 2014 2015 2016 2017 | |
State and Local Jurisdiction [Member] | New Jersey Division of Taxation [Member] | CII [Member] | ||
Income Tax Examination, Year under Examination | 2016 2017 2018 2019 |
Note 7 - Income Taxes - Compone
Note 7 - Income Taxes - Components of the Provision for Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Current - Federal | $ (40) | |
Current - State and local | 619 | 369 |
Deferred - Federal and state | 1,190 | 549 |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | (2,575) | (1,898) |
Income Tax Expense (Benefit), Total | $ (766) | $ (1,020) |
Note 7 - Income Taxes - Reconci
Note 7 - Income Taxes - Reconciliation of the Statutory Tax Rate to the Effective Tax Rate (Details) | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Statutory federal income tax rate | 21.00% | 21.00% |
Statutory state income tax rate | 9.50% | 9.50% |
Other state income tax rate | 2.50% | 2.50% |
Change in valuation allowance | (34.80%) | (69.00%) |
PPP Note forgiveness | (7.40%) | |
Other temporary differences | (1.40%) | 2.90% |
Non-deductible expenses | 0.00% | 0.10% |
Effective income tax rate | (10.60%) | (33.00%) |
Note 7 - Income Taxes - Signifi
Note 7 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Jun. 30, 2020 |
Net operating loss | $ 5,691 | $ 7,047 |
Capital loss carryover | 299 | 258 |
Valuation adjustment on investment in iBio, Inc. | 186 | 254 |
Depreciation | (158) | (204) |
Inventory | 128 | 142 |
Other | 195 | 34 |
Valuation allowance | (3,073) | (5,648) |
Total deferred tax asset, net | $ 3,268 | $ 1,883 |
Note 8 - Profit-sharing Plan (D
Note 8 - Profit-sharing Plan (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 73 | $ 68 |
Note 9 - Significant Risks an_2
Note 9 - Significant Risks and Uncertainties (Details Textual) | 12 Months Ended | |
Jun. 30, 2021USD ($) | Jun. 30, 2020 | |
Cash, FDIC Insured Amount | $ 250,000 | |
Cash, Uninsured Amount | $ 4 | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | ||
Number of Major Customers | 2 | 2 |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Contract Manufacturing [Member] | ||
Number of Major Customers | 2 | 2 |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member] | ||
Concentration Risk, Percentage | 92.00% | 92.00% |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member] | Contract Manufacturing [Member] | ||
Concentration Risk, Percentage | 69.00% | 26.00% |
Accounts Receivable [Member] | Customer Concentration Risk [Member] | ||
Number of Major Customers | 2 | |
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member] | ||
Concentration Risk, Percentage | 93.00% | 92.00% |
Revenue, Segment Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Branded Nutraceutical [Member] | ||
Concentration Risk, Percentage | 9.00% | 10.00% |
Number of Employees, Geographic Area [Member] | Unionized Employees Concentration Risk [Member] | ||
Concentration Risk, Percentage | 71.00% |
Note 10 - Commitments and Con_3
Note 10 - Commitments and Contingencies (Details Textual) $ in Thousands | May 19, 2014USD ($)ft² | Jan. 05, 2012USD ($)ft² | Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | Jan. 04, 2012ft² |
Operating Lease, Liability, Total | $ 2,370 | ||||
Rental of Office Equipment [Member] | |||||
Lessee, Operating Lease, Term of Contract (Year) | 5 years | ||||
Lessee, Operating Lease, Liability, Annual Commitment | $ 7 | ||||
Unrelated Party [Member] | |||||
Operating Lease, Expense | 1,057 | $ 1,040 | |||
Operating Lease, Liability, Total | $ 43 | ||||
Lessee, Operating Lease, Discount Rate | 3.75% | 3.75% | |||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 4 years 146 days | 5 years 146 days | |||
Manhattan Drug Company [Member] | |||||
Area of Real Estate Property (Square Foot) | ft² | 76,161 | 74,898 | |||
Payments for Rent | $ 533 | ||||
AgroLabs [Member] | |||||
Area of Real Estate Property (Square Foot) | ft² | 2,700 | ||||
Payments for Rent | $ 27 | ||||
Chairman, Chief Executive Office and Major Stockholder [Member] | |||||
Percent of Ownership for Warehouse and Office Facilities Leased | 100.00% | ||||
Vitamin Realty LLC [Member] | |||||
Operating Lease, Expense | $ 883 | $ 862 | |||
Due to Related Parties, Total | 65 | 62 | |||
Operating Lease, Liability, Total | $ 2,327 | $ 2,794 | |||
Vitamin Realty LLC [Member] | Operating Lease Renewed for Office Space [Member] | |||||
Lessee, Operating Lease, Term of Contract (Year) | 1 year | ||||
Lessee, Operating Lease, Liability, Annual Commitment | $ 25 | ||||
Minimum [Member] | |||||
Lessee, Lease, Term of Contract (Year) | 1 year | ||||
Maximum [Member] | |||||
Lessee, Lease, Term of Contract (Year) | 7 years |
Note 10 - Commitments and Con_4
Note 10 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Operating Lease Costs | $ 664 | $ 670 |
Amortization of right-of use assets | 24 | 57 |
Interest on operating lease liabilities | 2 | 13 |
Total Finance Lease Costs | 26 | 70 |
Unrelated Party [Member] | ||
Operating Lease Costs | 98 | 104 |
Amortization of right-of use assets | 24 | 57 |
Interest on operating lease liabilities | 2 | 13 |
Total Finance Lease Costs | 26 | 70 |
Vitamin Realty LLC [Member] | ||
Operating Lease Costs | 566 | 566 |
Amortization of right-of use assets | ||
Interest on operating lease liabilities | ||
Total Finance Lease Costs |
Note 10 - Commitments and Con_5
Note 10 - Commitments and Contingencies - Leases and Commitments (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Jun. 30, 2020 |
Operating lease right-of-use assets | $ 2,365 | $ 2,824 |
Current portion of operating lease liabilities | 500 | 488 |
Operating lease liabilities | 1,870 | 2,342 |
Remaining cash commitment | 2,586 | 3,141 |
Machinery and Equipment Leases [Member] | ||
Operating lease right-of-use assets | 5 | 16 |
Current portion of operating lease liabilities | 5 | 11 |
Operating lease liabilities | 5 | |
Remaining cash commitment | 5 | 16 |
Office Equipment Leases [Member] | ||
Operating lease right-of-use assets | 38 | 20 |
Current portion of operating lease liabilities | 10 | 10 |
Operating lease liabilities | 28 | 10 |
Remaining cash commitment | 44 | 22 |
Vitamin Realty LLC [Member] | ||
Operating lease right-of-use assets | 2,322 | 2,788 |
Current portion of operating lease liabilities | 485 | 467 |
Operating lease liabilities | 1,842 | 2,327 |
Remaining cash commitment | $ 2,537 | $ 3,103 |
Note 10 - Commitments and Con_6
Note 10 - Commitments and Contingencies - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Operating cash flows from operating leases | $ 663 | $ 657 |
Operating cash flows from finance lease obligations | 2 | 13 |
Financing cash flows from finance lease obligations | 75 | 194 |
Unrelated Party [Member] | ||
Operating cash flows from operating leases | 98 | 92 |
Operating cash flows from finance lease obligations | 2 | 13 |
Financing cash flows from finance lease obligations | 75 | 194 |
Vitamin Realty LLC [Member] | ||
Operating cash flows from operating leases | 565 | 565 |
Operating cash flows from finance lease obligations | ||
Financing cash flows from finance lease obligations |
Note 10 - Commitments and Con_7
Note 10 - Commitments and Contingencies - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Jun. 30, 2020 |
2022 | $ 582 | |
2023 | 574 | |
2024 | 572 | |
2025 | 542 | |
2026 | 316 | |
Total minimum lease payments | 2,586 | |
Imputed interest | (216) | |
Total | 2,370 | |
Vitamin Realty LLC [Member] | ||
2022 | 565 | |
2023 | 565 | |
2024 | 563 | |
2025 | 533 | |
2026 | 311 | |
Total minimum lease payments | 2,537 | |
Imputed interest | (210) | |
Total | 2,327 | $ 2,794 |
Unrelated Party [Member] | ||
2022 | 17 | |
2023 | 9 | |
2024 | 9 | |
2025 | 9 | |
2026 | 5 | |
Total minimum lease payments | 49 | |
Imputed interest | (6) | |
Total | $ 43 |
Note 12 - Equity Transactions_3
Note 12 - Equity Transactions and Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended | |
Nov. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 7,480,669 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 770,000 | ||
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) | $ 0.09 | ||
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share) | $ 0.72 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | ||
Share-based Payment Arrangement, Expense | $ 231 | $ 59 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | $ 2,825 | $ 846 | |
Director [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 770,000 | ||
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) | $ 0.65 | ||
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share) | $ 0.72 | ||
Share-based Payment Arrangement, Option [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 0 | 0 | |
Share-based Payment Arrangement, Option [Member] | Director [Member] | |||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 307 | ||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 182 days | ||
Share-based Payment Arrangement, Option [Member] | Director [Member] | Share-based Payment Arrangement, Tranche One [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 1 year | ||
Share-based Payment Arrangement, Option [Member] | Director [Member] | Share-based Payment Arrangement, Tranche Two [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | ||
Share-based Payment Arrangement, Option [Member] | Maximum [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||
Share-based Payment Arrangement, Option [Member] | Maximum [Member] | Director [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||
Share-based Payment Arrangement, Option [Member] | Minimum [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 5 years | ||
Share-based Payment Arrangement, Option [Member] | Minimum [Member] | Director [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 5 years | ||
Stock Option 2001 Plan [Member] | |||
Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Originally Authorized (in shares) | 7,000,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) | 6,000,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 13,000,000 | ||
Stock Option 1997 Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 5,000,000 |
Note 12 - Equity Transactions_4
Note 12 - Equity Transactions and Stock-based Compensation - Fair Value of Stock Option Using Black-Scholes Option Pricing Model (Details) | 12 Months Ended |
Jun. 30, 2021$ / shares | |
Dividend Rate | 0.00% |
Closing Price of Common Stock (in dollars per share) | $ 0.65 |
Minimum [Member] | |
Risk Free Interest Rate | 0.01% |
Volatility | 134.50% |
Term (Year) | 4 years 182 days |
Maximum [Member] | |
Risk Free Interest Rate | 0.78% |
Volatility | 185.50% |
Term (Year) | 10 years |
Note 12 - Equity Transactions_5
Note 12 - Equity Transactions and Stock-based Compensation - Summary of the Company's Stock Option Activity, and Related Information (Details) - $ / shares | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Balance (in shares) | 3,344,000 | 3,761,500 |
Balance (in dollars per share) | $ 0.16 | $ 0.16 |
Granted (in shares) | 770,000 | |
Granted (in dollars per share) | $ 0.66 | |
Exercised (in shares) | (157,334) | (80,000) |
Exercised (in dollars per share) | $ 0.15 | $ 0.09 |
Terminated (in shares) | (3,333) | (137,500) |
Terminated (in dollars per share) | $ 0.21 | $ 0.14 |
Expired (in shares) | (36,667) | (200,000) |
Expired (in dollars per share) | $ 0.21 | $ 0.10 |
Balance (in shares) | 3,916,666 | 3,344,000 |
Balance (in dollars per share) | $ 0.26 | $ 0.16 |
Exercisable (in shares) | 3,114,099 | 2,875,533 |
Exercisable (in dollars per share) | $ 0.19 | $ 0.16 |
Note 12 - Equity Transactions_6
Note 12 - Equity Transactions and Stock-based Compensation - Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (Details) - $ / shares | 12 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2019 | |
Range of Exercise Price, Lower Limit (in dollars per share) | $ 0.09 | ||
Range of Exercise Price, Upper Limit (in dollars per share) | $ 0.72 | ||
Outstanding (in shares) | 3,916,666 | 3,344,000 | 3,761,500 |
Weighted average exercise price (in dollars per share) | $ 0.26 | $ 0.16 | $ 0.16 |
Weighted Average Remaining Contractual Life (Year) | 6 years 255 days | ||
Exercisable (in shares) | 3,114,099 | 2,875,533 | |
Weighted Average Exercise Price, Exercisable (in dollars per share) | $ 0.19 | $ 0.16 | |
Range One [Member] | |||
Range of Exercise Price, Lower Limit (in dollars per share) | 0.09 | ||
Range of Exercise Price, Upper Limit (in dollars per share) | $ 0.10 | ||
Outstanding (in shares) | 1,301,000 | ||
Weighted average exercise price (in dollars per share) | $ 0.09 | ||
Weighted Average Remaining Contractual Life (Year) | 3 years 328 days | ||
Exercisable (in shares) | 1,301,000 | ||
Weighted Average Exercise Price, Exercisable (in dollars per share) | $ 0.09 | ||
Range Two [Member] | |||
Range of Exercise Price, Lower Limit (in dollars per share) | 0.21 | ||
Range of Exercise Price, Upper Limit (in dollars per share) | $ 0.21 | ||
Outstanding (in shares) | 1,295,666 | ||
Weighted average exercise price (in dollars per share) | $ 0.21 | ||
Weighted Average Remaining Contractual Life (Year) | 7 years 328 days | ||
Exercisable (in shares) | 1,104,766 | ||
Weighted Average Exercise Price, Exercisable (in dollars per share) | $ 0.21 | ||
Range Three [Member] | |||
Range of Exercise Price, Lower Limit (in dollars per share) | 0.23 | ||
Range of Exercise Price, Upper Limit (in dollars per share) | $ 0.25 | ||
Outstanding (in shares) | 550,000 | ||
Weighted average exercise price (in dollars per share) | $ 0.23 | ||
Weighted Average Remaining Contractual Life (Year) | 5 years 146 days | ||
Exercisable (in shares) | 508,333 | ||
Weighted Average Exercise Price, Exercisable (in dollars per share) | $ 0.23 | ||
Range Four [Member] | |||
Range of Exercise Price, Lower Limit (in dollars per share) | 0.65 | ||
Range of Exercise Price, Upper Limit (in dollars per share) | $ 0.65 | ||
Outstanding (in shares) | 620,000 | ||
Weighted average exercise price (in dollars per share) | $ 0.65 | ||
Weighted Average Remaining Contractual Life (Year) | 9 years 146 days | ||
Exercisable (in shares) | 150,000 | ||
Weighted Average Exercise Price, Exercisable (in dollars per share) | $ 0.65 | ||
Range Five [Member] | |||
Range of Exercise Price, Lower Limit (in dollars per share) | 0.72 | ||
Range of Exercise Price, Upper Limit (in dollars per share) | $ 0.72 | ||
Outstanding (in shares) | 150,000 | ||
Weighted average exercise price (in dollars per share) | $ 0.72 | ||
Weighted Average Remaining Contractual Life (Year) | 6 years 328 days | ||
Exercisable (in shares) | 50,000 | ||
Weighted Average Exercise Price, Exercisable (in dollars per share) | $ 0.72 |
Note 13 - Segment Information_2
Note 13 - Segment Information (Details Textual) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | |
Number of Reportable Segments | 2 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 63,559 | $ 52,769 |
Europe and Canada [Member] | ||
Revenue from Contract with Customer, Including Assessed Tax | $ 9,172 | $ 8,473 |
Note 13 - Segment Information -
Note 13 - Segment Information - Operations by Business Segment (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Sales, net | $ 63,559 | $ 52,769 |
Gross Profit | 9,480 | 6,727 |
Depreciation | 337 | 312 |
Capital Expenditures | 295 | 230 |
Total Assets | 25,440 | 22,944 |
Contract Manufacturing [Member] | ||
Sales, net | 61,835 | 51,326 |
Gross Profit | 9,020 | 6,427 |
Depreciation | 332 | 310 |
Capital Expenditures | 292 | 221 |
Total Assets | 21,333 | 19,581 |
Other Nutraceutical Business [Member] | ||
Sales, net | 1,724 | 1,443 |
Gross Profit | 460 | 300 |
Depreciation | 5 | 2 |
Capital Expenditures | 3 | 9 |
Total Assets | 4,107 | 3,363 |
UNITED STATES | ||
Sales, net | 54,387 | 44,296 |
UNITED STATES | Contract Manufacturing [Member] | ||
Sales, net | 52,763 | 42,944 |
UNITED STATES | Other Nutraceutical Business [Member] | ||
Sales, net | 1,624 | 1,352 |
Non-US [Member] | ||
Sales, net | 9,172 | 8,473 |
Non-US [Member] | Contract Manufacturing [Member] | ||
Sales, net | 9,072 | 8,382 |
Non-US [Member] | Other Nutraceutical Business [Member] | ||
Sales, net | $ 100 | $ 91 |